While there are drugs that target epigenetic regulators (e.g. Ezh2 inhibitors), it’s not clear yet how the new data would take advantage of them (if they can at all). While some of these drugs have shown promise, all of them have some drawbacks because they affect so many genes, often leading to unwanted toxicities. But hopefully this type of new data may help refine when to use which epigenetic drugs in which combinations.

Even so, epigenetic drugs may not always be the best answer to epigenetic dysregulation in cancer cells - remains to be seen though.